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DIFFERENTIAL CYTOSTATIC ACTIVITY OF MONOCYTE-DERIVED 
CYTOKINES AGAINST HUMAN MELANOMA CELLS
Anje A. te V e l d e1, Elly v .d . W iel-v . Kem en a d e  and Carl G. F ig d o r 2
Division o f  Immunology, The Netherlands Cancer Institute, Antoni, van Leeuwenhoek Huis, Plesmanlaan 121, 1066 C X  Amsterdam, 
The Netherlands.
We investigated the capacity of 3 major cytokines secreted by 
activated monocytes, IL-1 p, TNFa and IL-6, to inhibit growth of 
melanoma tumor cells. Using neutralizing antibodies against 
IL-lp, TNFtt and IL-6, we observed that the cytostatic activity 
against A375 melanoma cells is largely due to the presence of 
IL-6 in culture supernatants of monocytes stimulated with LPS. 
A375 cells appeared to be extremely sensitive to monocyte- 
derived cytokines, since in addition to rlL-6 also rIL-lp and 
rTNFtt displayed cytostatic activity against A375 cells. We 
observed additive or synergistic cytostatic effects upon use of 
combinations of these cytokines. When 7 other melanoma cell 
lines and short-term melanoma cultures were tested and 
compared with A375, a major difference in their sensitivity to 
monocyte-derived cytokines were observed. Although 7 out of 8 
melanoma cell lines were sensitive to culture supernatants of 
monocytes stimulated with LPS, significant differences were 
found when recombinant cytokines were used. The widely used 
A375 was the only melanoma cell line sensitive to rIL- Ip, rTNFa 
and rlL-6. The growth of none of the other 7 melanoma cell 
cultures was significantly affected by rIL-lp. Seven out of 8 
melanoma cell cultures were sensitive to rTNFa and 3 out of 8 
to rlL-6. The results of our study indicate that the sensitivity of 
melanoma cell cultures for different monocyte-derived cyto­
kines is highly variable, and that it is questionable whether the 
A375 melanoma cell line, sensitive to  rIL-1 p, rTNFa and rlL-6, is 
representative for melanoma.
Monocytes activated by LPS produce a number of cytokines 
with cytostatic activity for certain tumor cells. Dependent on 
the target cells used to measure anti-tumor cytostatic/cytotoxic 
activity of monocytes, various studies report that this effect 
must be ascribed to IL-1(B and TNFa secreted by monocytes 
(Onozaki et al, 1985; Ruggiero and Baglioni, 1987). If human 
A375 melanoma cells are used as target cells, both monokines, 
either alone or in combination, have been shown to possess 
potential anti-tumor effects (Ruggiero and Baglioni, 1987; 
Ichinose et a l, 1988; Nakai et a l, 1988). However, with the 
availability of recombinant cytokines, data are accumulating 
that many of the activities that were formerly ascribed to 
purified IL-1 preparations may be mediated by other contami­
nating cytokines present in the purified material (Wong and 
Clark, 1988; Helle et a l , 19886). Furthermore, the biological 
assays by which the IL-1 activity was determined were also 
found to be sensitive for TNFa and IL-6 (Wong and Clark, 
1988; Van Damme et a l, 1988). In addition, IL-1 can induce 
the production of IL-6 in monocytes (Tosato and Jones, 1990) 
and IL-1 and TNF can induce each other's release by mono­
cytes (Dinarello et a l , 1986). These observations prompted us 
to investigate the cytostatic activity of monocyte-derived IL-6.
Our results demonstrate that not IL-lp and/or TN Fa but 
IL-6 is the major cytokine with cytostatic activity against A375 
melanoma cells present in monocyte culture supernatant. 
However, the sensitivity of different melanoma cell lines to 
these 3 cytokines was highly variable.
MATERIAL AND METHODS 
Monocytes and monocyte culture
Human peripheral-blood monocytes were isolated and cul­
tured as described by Figdor et a l  (1982) and Te Velde et a l
(1988). Briefly, mononuclear cells were separated by density 
centrifugation with a blood-component separator, followed by
fractionation into lymphocytes and monocytes by centrifugal 
elutriation. Monocytes (>95%  pure) were cultured in Yssel’s 
medium (Yssel et al, 1984) containing human serum albumin 
and supplemented with 1% heat-inactivated human serum and 
1 jLtg/ml of LPS in a concentration of 4.106 cells per ml at 37°C, 
5% C 0 2 and 100% humidity in Teflon bags (Jansen MNL, St. 
Niklaas, Belgium), After culture for 4 hr, the culture superna­
tant was harvested and stored at —20°C until required.
Melanoma cell lines
The melanoma cell lines are: A375 (Giard et al, 1973), M14 
(Katano et a l, 1984), MeWo (Carey et al, 1976), Mel 518 A2 
(Versteeg et al, 1988) and BRO (Lockshin et al, 1985). The 
short-term-cultured (<  2 months in culture) HR, ZR and KZ 
were established from metastatic melanoma lesions in our 
laboratory. The melanoma cells were cultured in Iscove’s 
medium supplemented with 10% heat-inactivated FCS, 0.2 
mM glutamin and antibiotics. The melanoma cell lines were 
free of Mycoplasma contamination.
Recombinant cytokines and neutralizing antibodies
m
Recombinant human IL-ip (1,000 U /m l) was purchased 
from Boehringer, Mannheim, Germany. Human rTNFa (spe­
cific activity 6.107 U/ml) was provided by Boehringer In- 
gelheim, Vienna, Austria. Human rIL-6 (specific activity 109 
U /m g) and neutralizing goat anti-IL-6 antibodies were kindly 
provided by Drs. M. Helle and L A . Aarden (Brakenhoff et a l,  
1987) from the Central Laboratory of the Netherlands Red  
Cross Blood Transfusion Service (CLB), Amsterdam, The 
Netherlands. Human rGM-CSF (cos 7 culture supernatant) 
was a generous gift from Drs. P. Trotta and S. Nagabhushan 
(Schering-Plough, Bloomfield, NY). Neutralizing mouse anti- 
IL-lp monoclonal antibodies (MAbs) F1B1 and F1B3 were 
kindly provided by Dr. H. Herzbeck (Forschungsinstitut Bors- 
tel, Borstel, Germany). Neutralizing mouse anti-TNFa MAbs 
were a generous gift from Dr. R. Torensma (University of 
Utrecht, Utrecht, The Netherlands). Non-specific purified 
mouse anti-idiotype MAbs (K8) and normal goat serum were 
used as control antibodies.
Detection o f  IL-1 a, IL-1 ft, TNFa. and IL-6 in monocyte culture 
supernatant
IL-lct in the culture supernatant of human monocytes was 
tested using the IL -la  ELISA (Endogen, Boston, MA). The  
sensitivity of this assay is 50 pg/ml of IL -la  and there is no 
cross-reactivity with IL-lp, IL-2, IFNs, IL-6, TNFa, lympho- 
toxin or other cytokines.
IL -lp  in the culture supernatant of human monocytes was 
tested using the IL -lp  ELISA assay (Cistron, Pine Brook, N J). 
The sensitivity of this assay is 20 pg of IL-lp and there is no 
cross-reactivity with IL-la, IL-2 or TNFa.
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TNFa in the culture supernatant of human monocytes was 
tested using the Biokine TNF Test Kit (T-cell Sciences, 
Cambridge, MA). The sensitivity of this assay is 10 pg 
TNFa/m! and no detectable cross-reactivity with other de­
scribed cytokines can be observed.
IL-6 in the culture supernatant of human monocytes was 
tested using the R and D Systems Quantikine human IL-6 
immunoassay (Minneapolis, MN). The sensitivity of this assay 
is 3.5 pg/ml and it shows no detectable cross-reactivity with 
other known cytokines.
Growth inhibition assay
Melanoma cells were seeded (1,000/well of a 96-well plate) 
in Iscove’s medium supplemented with 10% heat-inactivated 
FCS in a volume of 100 \x\. After 72 hr of incubation at 37°C 
and 5% C 0 2 the cells were pulsed for 4 hr with 0.4 |jl Ci/mmol 
(NEN, Boston, MA), after which the cells were harvested and 
counted. The data are expressed as percentage growth inhibi­
tion calculated by the formula:
growth inhibition = 1
cpm test sample
cpm medium (no additives)
X 100%
TABLE I -  SECRETION O F MONOKINES BY D IFFE R E N T  CULTURES OF
4-HR LPS-ACTIVATED M ONOCYTES
Monokine
Monokine secretion
ng/ml U/ml
n
IL-la
IL-lß
TNFa
IL-6
Mean (range)
<0.1 
9.9 (2-25) 
20.5 (0.5-445  
22.0 (3.0-30.0
Mean (range)
330 (60-830 
340 (10-740 
14,700 (2000-19,500)
3 
8 
5
4
Blocking o f  cytostatic activity o f  monocyte culture supernatant by 
neutra lizing a n tibodies
We have shown that monocyte culture supernatant con­
tained factors with cytostatic activity for A375 cells (Te Velde 
e ta l ,  1988). Monocytes activated by LPS rapidly secrete IL-lp, 
TNFa and IL-6. The concentration of the secreted monokines 
varies between monocyte cultures from different donors as 
shown in Table I. To investigate whether IL -lp , TN Fa and/or  
IL-6 were responsible for the cytostatic activity found in 
culture supernatant of LPS-activated monocytes, we per­
formed blocking experiments with antibodies in saturating 
concentrations that neutralized cytokine activity. Figure la  
shows a dose-response curve of the growth-inhibitory effect of 
monocyte culture supernatant on the melanoma cell line A375. 
The results indicate that 5% culture supernatant causes 
maximal growth inhibition. MAbs against IL -lp  did not 
neutralize the cytostatic activity present in high concentrations 
in the monocyte supernatants (Fig. lb ) .  Also anti-TNFa MAb 
alone did not cause significant reduction of maximal cytostatic 
activity. Since IL-lp and T N Fa can act synergistically on 
several tumor cell lines (Ruggiero and Baglioni, 1987), we 
studied the effect of combinations of anti-IL-l(3 MAb with 
anti-TNFa MAb (Fig. lc ) . However, no additional blocking of 
the cytostatic activity by either anti-IL-1 p or anti-TNFa was 
observed. Only at dilutions of the monocyte supernatant of 
1:100 to 1:500 could a 50% reduction of the inhibition of 
cytostatic activity be observed with anti-IL-lp and/or anti- 
TNFa antibodies (Fig. 1, b, c ). These data indicate that the 
cytostatic activity is not mediated via IL -lp  and/or TNFa and 
must be ascribed to other cytokines produced by monocytes 
after LPS stimulation. Because IL-1 and IL-6 have a number of 
overlapping activities (Wong and Clark, 1988) and since IL-1
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F ig u r e  1 -  Blocking of the cytostatic activity present in monocyte culture supernatant with neutralizing antibodies directed against 
cytokines. The monocyte culture supernatant contained average concentrations of the different cytokines: 7 ng/ml of IL-ip, 14 ng/ml of 
TN Fa and 25 ng of IL-6. Growth inhibition of A375 melanoma cells was determined as described in the text. The following antibodies 
were tested: control mouse MAb K8 (for anti-IL-lp and anti-TNFa), control NGS (for anti-IL-6), anti-IL-lp, anti-TNFa and/or 
anti-IL-6. The anti-IL-1 p antibodies were used in a concentration of 100 |xg/ml and the anti-TNFa and anti-IL-6 antibodies were used in 
a dilution of 1/100. These antibody concentrations neutralized 100 U of rIL-ip, 10,000 U of rTNFa and 10,000 U of rIL-6 for 75,83 and 
95%, respectively. Results of 1 representative experiment out of 3.
748 TE VELDE ET AL.
can induce IL-6 activity (Tosato and Jones, 1990), we tested 
the effect of anti-IL-6 antibodies on the cytostatic capacity of 
LPS-activated monocyte culture supernatants. As shown in 
Figure Id , addition of anti-IL-6 antibodies almost completely 
abrogates the growth-inhibitory capacity of the monocyte 
supernatant. Combination of anti-IL-6 MAb with anti-IL-lp 
MAb and/or anti-TNFa MAb did not cause additional effects 
(Fig. le, ƒ). Anti-IL-lp and/or anti-TNFa cause a 50% 
reduction of the cytostatic activity in the presence of low 
concentrations of IL-6, indicating that IL-lp  and/or TNFa  
have synergistic or additive effects on the cytostatic activity at 
low concentrations of IL-6.
Taken together, our results indicate that IL-lp  and/or 
TNFa are not the factors in activated monocyte supernatants 
that are responsible for cytostatic effects against human A375 
cells, but that IL-6 appears to be the major cytokine with 
cytostatic activity against A375 cells produced by activated 
monocytes.
The finding that IL-6 is the major cytokine with cytostatic 
activity in monocyte culture supernatant does not exclude 
IL-lp and/or TNFa possessing cytostatic activity. To investi­
gate whether IL-lp and/or TN Fa have cytostatic activity 
against the human melanoma cell line A375> we performed a 
growth-inhibition assay with recombinant cytokines. The re­
sults (Fig. 2) demonstrate that rIL-6 as well as rIL-ip and 
rTNFa have a cytostatic effect on A375 cells in a dose- 
dependent fashion. Biologically effective concentrations of 
another monocyte-derived cytokine (rGM-CSF) did not dis­
play cytostatic activity. Purified recombinant forms of IL-lp  
and TNFa display marked cytostatic activity, but the concentra­
tions needed to measure this exceed the concentrations 
present in monocyte culture supernatants. To exclude the 
possibility that the monocyte supernatants contain inhibitors 
of monokine activity, recombinant cytokines were added to the 
monocyte culture supernatants. N o inhibition of the activity of 
the recombinant cytokines was found (data not shown), 
suggesting that the inability of IL -lp  and TN Fa to mediate 
cytostatic activity was not caused by secretion of inhibitory 
factors by the monocytes. To show that the lack of neutralizing 
capacity of anti-IL-lp MAb and anti-TNFa MAb was not 
caused by a general inability of the antibodies to neutralize 
cytokine activity, we performed blocking experiments with 
purified recombinant cytokines. We show that anti-IL-lp MAb 
as well as anti-TNFa and anti-IL-6 MAbs specifically block the
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Figure 2 -  Effect of recombinant monokines on the growth of 
A375 melanoma cells; 10-fold dilutions of the different recombi­
nant monokines. The following monokines are used: IL-lp (O) 
100 U/ml, TNFa ( • )  and IL-6 (□ )  10,000 U/ml and GM-CSF 
(■ )  5%/ml. The growth inhibition assay was performed as 
described in the text. Results of 1 representative experiment out 
of 5.
T N F  (U /m l)
IL-6 (U /m l)
IL-6 (U/ml)
Figure 3 -Effect of combinations of rIL-lp and/or rTNFa 
and/or rIL-6 on the growth of A375 melanoma cells. The growth- 
inhibition assay was performed as described in the text. Results of 
1 representative experiment out of 3.
respective cytostatic effects of the recombinant cytokines on  
A375 melanoma cells (results not shown).
In conclusion, our data indicate that IL-6 is the main factor 
in mediating monocyte cytostatic activity against A375 mela­
noma cells.
Additive and synergistic effects o fr IL -I  p, rTNFa and rIL-6
The data shown in Figure 1 (b and c) suggest that low 
concentrations of IL-lp, TNFa and IL-6, IL-lp and/or TNFa  
present in diluted monocyte supernatants can exert synergistic 
or additive effects with IL-6 on the growth of the A375 
melanoma cell line. Therefore we investigated mixtures of low  
doses of rIL-lp and rTNFa, rIL-lp and rIL-6, and rTNFa and
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rIL-6 in a growth-inhibition assay using A375 cells. Additive or 
sometimes synergistic effects can be observed if rIL-ip and 
rTNFa are combined (Fig. 3a). However, much higher anti- 
tumor activity was observed when IL~ip and IL-6 were 
combined (Fig. 3b). True synergistic effects were measured 
when IL-6 was combined with low concentrations of TNFa  
(Fig. 3c). Concentrations of IL-1 (3 and TNFa, which by 
themselves have low cytostatic activity on A375 cells, are 
effective if combined with low concentrations of IL-6. These 
results indicate that low concentrations of IL-ip, TNFa and 
IL-6 administered together have additive or synergistic effects 
on the growth of A375 cells.
Effect of IL-1 p, TNFa and IL-6 on melanoma cells other than 
A375
A375 melanoma cells are extremely sensitive to monocyte- 
derived cytostatic factors and this cell line is the most com­
monly used target in these assays (Ruggiero and Baglioni, 
1987; Ichinose et al, 1988; Nakai et ai, 1988). We were 
interested to determine whether other melanoma cell lines 
were sensitive to monocyte-derived cytokines, and especially if 
these cells were also sensitive to IL-6. The cytostatic effect of 
monocyte supernatant (after 4 hr incubation with LPS) was 
compared with that of recombinant IL -lp s TNFa, IL-6 and 
GM-CSF and tested on 4 different melanoma cell lines (Fig. 
4). A375 and M14 are equally sensitive to cytostatic factors 
present in the monocyte culture supernatant, followed by Mel 
518 A2 and MeWo, which appear to be insensitive to factors 
present in this supernatant. Exposure of the melanoma cells to 
the different recombinant monokines showed that only A375 
cells are sensitive to rIL-ip, whereas A375, M14 and Mel 518 
A2 are sensitive to rTNFa (Fig. 4). The growth of MeWo, 
which is not sensitive to monocyte-supernatant-derived fac­
tors, is affected neither by rTNFa nor by IL-1 (3, IL-6 affects the 
growth of both A375 and M14, although the latter is less 
sensitive. MeWo and Mel 518 A2 are relatively insensitive to 
rIL-6. rGM-CSF has no significant effect on the growth of any
of the melanoma cell lines tested (Fig. 4). Table II shows the 
comparison of the A375 melanoma cell line with a cell line 
derived from a primary melanoma lesion and 3 short-term 
cultures ( <  2-month culture) of a metastatic melanoma lesion. 
Despite the low proliferative capacity exhibited by the short­
term cultures, we found that these cultures also display 
variability in sensitivity to cytokines.
From these data we conclude that, as illustrated by this 
randomly chosen panel of melanoma cell lines and short-term 
cultures, the sensitivity of melanoma cells for monocyte- 
derived factors is highly variable.
DISCUSSION
The monocyte-mediated cytostatic activity against A375 
melanoma cells can be ascribed to IL-6. Both rIL-ip and 
rTNFa display cytostatic activity against A375 cells, but 
compared with IL-6 the contribution of these monokines in 
monocyte supernatants to inhibit cell growth is limited. These 
results are in accordance with the data of a number of groups 
who describe similar cytostatic activity of rIL-ip and rTNFa on 
various tumor cell lines (Ruggiero and Baglioni, 1987; Ichinose 
et al, 1988; Nakai et a i , 1988; Mortarini et al., 1990) which can 
be blocked using specific anti-sera (Ichinose etal, 1988; Nakai 
et ai, 1988). However, several reports show cytotoxic/ 
cytostatic activity of IL-1 using a natural purified form derived 
from monocyte supernatants (Onozaki et ai, 1985; Lachman et 
al, 1986). The biologic activity of these IL-1 preparations was 
determined with the murine thymocyte co-stimulatory assay. 
This assay is not specific for IL-1, since T N Fa (Hurme, 1988) 
and IL-6 (Van Damme et al, 1988) also contribute to thymo­
cyte proliferation. Indeed, some of the purified natural IL-1 
preparations were shown to be contaminated with IL-6 (Helle 
et al., 1988a). Moreover, anti-IL-1 anti-sera raised against 
monocyte culture medium contained anti-IL-6 activity (Aar- 
den et al, 1987). It can therefore not be excluded that at least
mo-jup (%) IL-1 > (U/ml) TNF a CU/ml)
A375 
M14 
MeWo 
Mel 518 A2
IL-6 (U/ml) GM-CSF (%)
F ig u r e  4 -Effect of increasing concentrations of LPS-activated monocyte supernatant (a), rIL-ip (b), rTNFa (c), rIL-6 (d) or 
rGM-CSF (e) on the growth of 4 different melanoma cell lines. The growth-inhibition assay was performed as described in the text. 
Results of 1 representative experiment out of 3.
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TABLE II -  COMPARISON OF THE EFFECT O F MONOKINES ON TH E G RO W TH  OF A M ELANOM A CELL LINE 
D ERIV ED  FROM A PRIMARY MELANOMA LESION AND 3 D IFFE R E N T  PRIM ARY CULTURES O F A
METASTATIC MELANOMA LESION WITH TH E A375 M ELANOM A CELL LINE
Maximum
Name 3I-I-thymidine mo-sup2 IL-ip
incorporation1
T N F a IL-6 GM-CSF
A375 29855 903 45 59 73 6
Cell line of a primary melanoma lesion:
BRO 16609 47 10 45 0 0
Primary cultures of metastatic melanoma lesion: 
HR 4924 34 5 21 22 0
ZR 2548 47 3 43 7 0
KZ '1609 55 11 30 4 1
‘Melanoma cultures were incubated with 3H-tliymidine for 4 hr after culture for 72 hr in the presence of various 
cytokines or monocyte culture supernatant (mo-sup),-2The following cytokines are used; 20% mo-sup, 100 U/ml of 
rIL-lp, 10,000 U of rTNFa, 10,000 U of rIL-6 or 5% /ml of rGM-CSF cos cell culture supernatant.-^The data are 
presented as % growth inhibition. The growth-inhibition assay was performed as described in the text.
part of the reported cytostatic activity ascribed to IL-1 must be 
attributed to TNFa and IL-6.
When the contribution of different cytostatic factors present 
in monocyte supernatant was compared with single and com­
bined recombinant factors a discrepancy was observed (Figs, 
1-3). In principle, cytokines present in monocyte culture 
supernatants should not behave differently from recombinant 
cytokines. However, the ultimate growth-inhibitory capacity of 
a monocyte culture supernatant is an end result of both 
inhibitory and stimulatory activities. The inability of anti-IL-lp 
and anti-TNFa to block monocyte-mediated growth inhibition 
could not be ascribed to IL-1 (3 and TNFa inactivity caused by 
inhibitors present in the culture medium, inasmuch as addition 
of rIL-lp o r  rTNFa to the monocyte culture supernatant 
inhibited tumor growth (results not shown). A  possible expla­
nation for this finding is that, compared with IL-lp and TNFa, 
monocytes produce much higher levels of IL-6 activity. In 
Table I it was shown that 5% monocyte supernatant causing 
maximal growth inhibition (Fig. 1) contains approximately 16,5 
U  of IL-1 (3, 17 U  of TNFa and 735 U of IL-6. However, since 
the units for IL-1 (3, TNFa and IL-6.are determined in different 
assays, a direct comparison of relative activity based on these 
units is not justified. Moreover, factors as yet unidentified may 
influence the result obtained with monocyte culture superna­
tant.
The exact mechanism of regulation of monokine production 
remains largely unknown, the more so as IL-1, TNFa and IL-6 
can influence each other’s release (Dinarello, 1989). In addi­
tion, not only monocytes but also melanoma cells produce IL-1 
and IL-6. Melanoma cells have the capacity to produce IL-la  
(Köck et a l ,  1989; Benicelli et a l } 1989) and Morinaga et a l
(1989) have demonstrated that IL-1-sensitive melanoma cells 
can produce IL-6 upon treatment with IL-la, the elaborated 
IL-6 acting as an autocrine inhibitor of cell proliferation, 
However, IL-6 production was moderate and resulted in a 
growth inhibition of less than 30%, The finding that melanoma 
cells secrete IL -la  and that IL -la  is involved in stimulation of 
melanoma cell IL-6 production suggests that regulation of 
cytokine secretion is complex. An important point that re­
quires further investigation is whether melanoma cells also 
produce cytokines in vivo or whether the observed capacity to 
secrete cytokines is acquired by in vitro culturing.
Compared with 3 other melanoma cell lines which are 
relatively insensitive to one or more of the monocyte-derived 
cytokines, the A375 melanoma cell line is unique, since it is 
sensitive to rIL-lp, rTNFa and rIL-6 (Fig. 4). This cell line is 
therefore unsuitable for measuring IL-1 activity in a bioassay, 
as suggested by Nakai et a l  (1988), since effects of TNFa and 
IL-6 cannot be excluded. The observed sensitivity for IL-6 
appears to be confined to only a few melanoma cell lines: only
3 out of 8 melanoma cultures are more or less sensitive for 
IL-6. So it is questionable whether the A375 cell line is 
representative for melanoma in general.
ACKNOWLEDGEMENTS
We thank Dr. C.J.M. Melief for critical reading of the 
manuscript, Mr. R.J.F. Huijbens for technical assistance and 
Mrs. M.A. van Halem for secretarial help. This work is 
supported by a grant from the Dutch Cancer Society (grant 
N K I86-1).
REFERENCES
A a r d e n ,  L.A., B r a c k e n h o f f ,  D e  G r o o t ,  E.R. and H e l l e ,  M„ 
In: F. M elchers and M. Potter (eds.), Mechanism ofB cell neoplasia, pp. 
91-98, R oche, Basel (1987).
B e n n i c e l l i ,  J .L ., E l i a s ,  J., K e r n ,  J. and G u e r r y ,  D., Production of 
interleukin-1 activity by cultured human melanoma cells. Cancer Res., 
49, 930-935 (1989),
B r a k e n h o f f ,  J .P .J .,  D e  G r o o t ,  E .R ., E v e r s ,  R.F., P a n n e k o e k ,  H. 
and A a r d e n ,  L.A., M olecular cloning and expression of hybridoma 
growth factor in E. colt J. Im m u n o l139,4116-4121 (1987).
C a r e y ,  T .E .,  T a k a h a s h i ,  T ., R e s n ic k , L.A., O e t t g e n ,  H.F. and O ld ,  
L .J ., Cell-surface antigens of human malignant melanoma: mixed 
hem adsorption assays for humoral immunity to cultured autologous 
m elanom a cells, Proc. nat. Acad . Set (Wash.), 73, 3278-3282 (1976).
D i n a r e l l o ,  C .A ., Interleukin-1 and its biologically related cytokines. 
Adv. Immunol, 4 4 ,1 5 3 -2 0 5  (1989).
D i n a r e l l o ,  C .A ., C a n n o n ,  J .G ., W o l f f ,  S.M ., B e rn h e im , H .A ., 
B e u t l e r ,  B., C e r a m i ,  A ., F i g a r i ,  I.S., P a l l a d i n o  J r . ,  M .A. and 
O 'C o n n o r ,  J .V ., Tum or necrosis factor (cachectin) is an endogenous
pyrogen and induces production o f interleukin 1, I. exp. Med., 163, 
1433-1450(1986).
F i g d o r ,  C.G., B o n t ,  W.S., T o u w , I., R o o s ,  D ., R o o s n k , E.E. and De 
V r ie s ,  J.E., Isolation o f functionally different human monocytes by 
counterflow centrifugation élutriation. Blood, 60 ,46-53  (1982).
G i a r d ,  D .J ., A a r o n s o n ,  S.A., T o d a r o ,  G .J ., A r n s t e in ,  P., K ersey , 
J.H., D o sik , H. and P a r k s ,  W.P., In vitro cultivation o f human tumors: 
establishment o f cell lines derived from a series of solid tumors. J. nat. 
Cancer Inst., 51 ,1417-1423 (1973).
H e l l e ,  M., B o e ije ,  L. and A a r d e n ,  L.A., Functional discrimination 
between interleukin 6 and interleukin 1. Europ. I. Immunol., 18,
1535-1540 (1988a).
H e l l e ,  M., B r a k e n h o f f ,  J.P.J., D e  G r o o t ,  E .R . and A a r d e n ,  L.A.,
Interleukin 6 is involved in interleukin 1-induced activities. Europ. I. 
Immunol, 18 ,957-959 (19886).
H u r m e ,  M., Both interleukin 1 and tumor necrosis factor enhance 
thymocyte proliferation. Europ. J. Immunol, 18,1303-1306 (1988).
I c h in o s e ,  Y., T s a o ,  J.Y, and F i d l e r ,  I.J ., Destruction of tumor cells
CYTOSTASIS OF MONOKINES FOR MELANOMA CELLS 751
by monokines released from activated human blood monocytes: 
evidence for parallel and additive effects o f IL-1 and TN F. Cancer 
Immunol. Immunother., 2 7 ,7-12  (1988).
Katano , M., Sa x t o n , R.E., C o c h r a n , A J . and I r i e , R.F., E stablish­
ment of an ascitic human melanoma cell line that m etastasizes to lung  
and liver in nude m ice ./. Cancer Res. clin. Oncol., 108 ,197-203  (1984).
Kock, A., Sc h w a r z , T ., U rbanski, A ., P e n g , Z., V e t t e r l e in , M., 
M icksche, M,, A n sel , J.C., K u n g , H.F. and L u g e r , T.A., Expression  
and release o f interleukin-1 by different hum an m elanom a cell lines. J. 
nat. Cancer Inst., 8 1 ,36-42  (1989).
Lachm an , L.B., D in a r e l l o , C.A., L l a n s a , N .D . and F id l e r , I.J., 
Natural and recombinant human interleukin l-(3 is cytotoxic for 
human melanoma ce lls ./. Immunol, 1 3 6 ,3098-3102 (1986).
Lockshin , A ., G io v a n e l l a , B.C., D e  Ip o l y i , P .D .,  W il l ia m s , L .J ., 
M e n d o z a , J .T ., Y im , S .O . and St e h l in , J .S ., Exceptional lethality for 
nude mice of cells derived from a primary human m elanom a. Cancer 
Res., 4 5 ,345-350 (1985).
M o r in a g a , Y ., Su z u k i , H ., T a k a tsu k i, F ., A k iy a m a , Y ., T a n iy a m a , 
T., M a tsu sh im a , K. and O n o z a k i , K., Contribution o f IL -6 to the  
anti-proliferative effect o f IL-1 and tumor necrosis factor on tumor cell 
lines./. Immunol, 1 4 3 ,3538-3542 (1989).
M o r t a r in i , R., B e l l i , F., P a r m ia n i , G. and A n ic h in i , A ., Cvtokine- 
mediated modulation o f HLA-class II, I-CAM -1, LFA-3 and tumor- 
associated antigen profile of melanoma cells, Comparison with anti­
proliferative activity by rIL-l-p, rTNF-a, rIFN -7 , rIL4 and their 
combinations. Int. I. Cancer, 4 5 ,334-341 (1990),
Nakai, S., M iz u n o , K., K a n e t a , M. and H ir a i , Y ,, A  sim ple, sensitive  
bioassay for the detection o f interleukin- 1 using human m elanom a  
A375 cell line. Biochem. biophys. Res. Comm., 1 5 4 ,1189-1196 (1988).
O n o z a k i , K., M a t s u s h im a , K ., K l e in e r m a n , E .S., S a it o , T. and 
O p p e n h e im , J.J., R ole o f  interleukin 1 in prom oting human m onocyte- 
m ediated tumor cytotoxicity. /  Immunol, 135, 314—320 (1985).
R u g g i e r o , V. and Ba g l io n i , C., Synergistic anti-proliferative activity 
of interleukin 1 and tum or necrosis factor. I. Im munol, 138, 661-663  
(1987).
T e  V e l d e , A .A ., K l o m p , J.P.G ., Y a r d , B .A ., D e  V r ie s , J.E. and 
F i g d o r , C.G ., M odulation o f phenotypic and functional properties o f  
human peripheral blood m onocytes by IL-4. / .  Immunol, 140, 1548- 
1554(1988).
T o s a t o ,  G. and J o n e s ,  K .D ., Interleukin -1 induces interleukin-6 
production in peripheral-blood m onocytes. Blood, IS, 1305-1310  
(1990),
V a n  D a m m e , J., V an B e e u m e n , J., D e c o c k , B., V a n  Sn ic k , J., D e  
L e y , M. and B il l ia u , A ., Separation and com parison o f two m onok­
ines with lymphocyte-activating factor activity: IL-1 (3 and hybridoma 
growth factor (H G F). Identification o f leukocyte-derived H G F as 
IL-6. / . Immunol, 1 4 0 ,1534-1541 (1988).
V e r s t e e g , R ., N o o r d e r m e e r , I.A ., K r u s e -W o l t e r s , M ., R u it e r , 
D.J. and S c h r ie r , P.I,, C-myc dow n-regulates class-I-H L A  expression  
in human m elanom as, EMBOJ,, 7 ,1 0 2 3 -1 0 2 9  (1988).
W o n g , G.G. and C l a r k , S.C., M ultiple actions o f interleukin 6 within 
a cytokine network. Immunol Today, 9 ,1 3 7 -1 3 9  (1988).
Y s s e l , H ., D e  V r ie s , J.E,, K o k e n , M ., V a n  B l it t e r s w h k , W. and 
Sp it s , H ., Serum -free m edium  for generation  and propagation o f  
functional human cytotoxic and helper T -cell clones. J. immunol 
Methods, 72, 219-227 (1984).
